Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ABCL Stock Forecast 2025-2026
$3.69
Current Price
$1.10B
Market Cap
Buy 6
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to ABCL Price Targets
+360.7%
To High Target of $17.00
+130.4%
To Median Target of $8.50
+8.4%
To Low Target of $4.00
ABCL Price Momentum
-5.6%
1 Week Change
-39.5%
1 Month Change
+39.2%
1 Year Change
+25.9%
Year-to-Date Change
-43.4%
From 52W High of $6.52
+95.1%
From 52W Low of $1.89
📊 TOP ANALYST CALLS
Did ABCL Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if AbCellera is one of their latest high-conviction picks.
Latest ABCL Stock Price Targets & Analyst Predictions
Based on our analysis of 13 Wall Street analysts, ABCL has a bullish consensus with a median price target of $8.50 (ranging from $4.00 to $17.00). The overall analyst rating is Strong Buy (8.8/10). Currently trading at $3.69, the median forecast implies a 130.4% upside. This outlook is supported by 6 Buy, 2 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Stephen Willey at Stifel, projecting a 360.7% upside. Conversely, the most conservative target is provided by Faisal Khurshid at Leerink Partners, suggesting a 8.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ABCL Analyst Ratings
6
Buy
2
Hold
0
Sell
ABCL Price Target Range
Low
$4.00
Average
$8.50
High
$17.00
Current: $3.69
Latest ABCL Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ABCL.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 7, 2025 | Leerink Partners | Faisal Khurshid | Market Perform | Downgrade | $4.00 |
| Aug 8, 2025 | Stifel | Stephen Willey | Buy | Maintains | $7.00 |
| Jul 14, 2025 | Keybanc | Scott Schoenhaus | Overweight | Maintains | $10.00 |
| Jul 7, 2025 | Leerink Partners | Faisal Khurshid | Outperform | Assumes | $5.00 |
| May 16, 2025 | Truist Securities | Robyn Karnauskas | Buy | Maintains | $10.00 |
| May 9, 2025 | Stifel | Buy | Maintains | $N/A | |
| Apr 16, 2025 | Keybanc | Scott Schoenhaus | Overweight | Maintains | $5.00 |
| Mar 3, 2025 | Benchmark | Robert Wasserman | Hold | Reiterates | $N/A |
| Feb 28, 2025 | Stifel | Stephen Willey | Buy | Maintains | $10.00 |
| Jan 8, 2025 | Keybanc | Scott Schoenhaus | Overweight | Maintains | $4.00 |
| Nov 5, 2024 | Stifel | Stephen Willey | Buy | Reiterates | $12.00 |
| Nov 5, 2024 | Benchmark | Robert Wasserman | Hold | Reiterates | $N/A |
| Aug 20, 2024 | Benchmark | Robert Wasserman | Hold | Downgrade | $N/A |
| Jul 11, 2024 | Keybanc | Scott Schoenhaus | Overweight | Maintains | $5.00 |
| May 8, 2024 | Keybanc | Scott Schoenhaus | Overweight | Maintains | $7.00 |
| Feb 22, 2024 | Benchmark | Robert Wasserman | Buy | Upgrade | $N/A |
| Feb 21, 2024 | Stifel | Stephen Willey | Buy | Maintains | $17.00 |
| Dec 5, 2023 | Keybanc | Scott Schoenhaus | Overweight | Initiates | $6.00 |
| Oct 13, 2023 | Piper Sandler | Allison Bratzel | Overweight | Assumes | $20.00 |
| Aug 31, 2023 | Benchmark | Robert Wasserman | Buy | Maintains | $12.00 |
AbCellera Biologics Inc. (ABCL) Competitors
The following stocks are similar to AbCellera based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
AbCellera Biologics Inc. (ABCL) Financial Data
AbCellera Biologics Inc. has a market capitalization of $1.10B with a P/E ratio of -6.7x. The company generates $35.33M in trailing twelve-month revenue with a 100.0% profit margin.
Revenue growth is +37.6% quarter-over-quarter, while maintaining an operating margin of -851.8% and return on equity of -16.8%.
Valuation Metrics
Market Cap
$1.10B
Enterprise Value
$828.46M
P/E Ratio
-6.7x
PEG Ratio
-0.6x
Price/Sales
30.7x
Growth & Margins
Revenue Growth (YoY)
+37.6%
Gross Margin
N/A
Operating Margin
-851.8%
Net Margin
+100.0%
EPS Growth
+37.6%
Financial Health
Cash/Price Ratio
+44.9%
Current Ratio
10.1x
Debt/Equity
14.2x
ROE
-16.8%
ROA
-10.4%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
AbCellera Biologics Inc. (ABCL) Business Model
About AbCellera Biologics Inc.
What They Do
Develops antibody therapies using innovative technology.
Business Model
The company collaborates with pharmaceutical and biotechnology firms to discover and develop antibody-based treatments. It generates revenue by leveraging its advanced technology platform, which combines high-throughput screening and proprietary microfluidics, to identify therapeutic antibodies rapidly, thus accelerating the drug development pipeline.
Additional Information
Founded in 2012 and based in Vancouver, Canada, AbCellera is a key player in personalized medicine and addressing complex diseases like cancer and infectious diseases. Its partnerships with leading biotech firms enhance its ability to provide novel therapeutic solutions, solidifying its position in the competitive biotechnology sector.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
596
CEO
Dr. Carl L.G. Hansen Ph.D.
Country
Canada
IPO Year
2020
Website
www.abcellera.comAbCellera Biologics Inc. (ABCL) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
AbCellera Biologics Inc. (ABCL) Reports Q3 Loss, Tops Revenue Estimates
ABCELLERA BIOLG (ABCL) delivered earnings and revenue surprises of -11.76% and +35.31%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Nov 06, 2025
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
AbCellera has appointed Dr. Stephen Quake to its Board of Directors, as announced in a recent press release.
Why It Matters
Dr. Quake's appointment could enhance AbCellera's strategic direction and innovation, potentially boosting investor confidence and influencing stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
AbCellera Biologics Inc. will hold its Q3 2025 earnings call on November 6, 2025, at 5:00 PM EST, featuring key executives and analysts from major financial institutions.
Why It Matters
AbCellera's Q3 earnings call provides insights into financial performance and strategic direction, crucial for evaluating its growth potential and investment viability.
Source: Seeking Alpha
Market Sentiment:
Neutral
AbCellera Reports Q3 2025 Business Results
8 days ago
Quick Summary
AbCellera has released its Q3 2025 business results, as reported from Vancouver, British Columbia. Further details on performance metrics were not provided in the excerpt.
Why It Matters
AbCellera's Q3 2025 results can impact stock performance, indicating financial health, growth potential, and market competitiveness, crucial for investment decisions.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
AbCellera Biologics Inc. reported a quarterly loss of $0.19 per share, exceeding the Zacks Consensus Estimate of a $0.17 loss, and compared to a loss of $0.17 per share the previous year.
Why It Matters
AbCellera's larger-than-expected quarterly loss signals potential operational challenges, which may affect investor confidence and the stock's performance.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
AbCellera will participate in investor conferences in November and December 2025, which may present opportunities for investor engagement and insights into the company's performance.
Why It Matters
AbCellera's participation in investor conferences may indicate potential developments or strategic updates, influencing investor sentiment and stock performance in the biotech sector.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
AbCellera Biologics is nearing completion of a clinical manufacturing facility, shifting to proprietary drug development. Key candidates are in trials, with revenue expected to double by 2026 despite recent declines.
Why It Matters
AbCellera's transition to proprietary drug development and in-house manufacturing positions it for significant growth, especially with promising clinical candidates and a strong financial outlook.
Source: Seeking Alpha
Market Sentiment:
Positive
Frequently Asked Questions About ABCL Stock
What is AbCellera Biologics Inc.'s (ABCL) stock forecast for 2026?
Based on our analysis of 13 Wall Street analysts, AbCellera Biologics Inc. (ABCL) has a median price target of $8.50. The highest price target is $17.00 and the lowest is $4.00.
Is ABCL stock a good investment in 2026?
According to current analyst ratings, ABCL has 6 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $3.69. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ABCL stock?
Wall Street analysts predict ABCL stock could reach $8.50 in the next 12 months. This represents a 130.4% increase from the current price of $3.69. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is AbCellera Biologics Inc.'s business model?
The company collaborates with pharmaceutical and biotechnology firms to discover and develop antibody-based treatments. It generates revenue by leveraging its advanced technology platform, which combines high-throughput screening and proprietary microfluidics, to identify therapeutic antibodies rapidly, thus accelerating the drug development pipeline.
What is the highest forecasted price for ABCL AbCellera Biologics Inc.?
The highest price target for ABCL is $17.00 from Stephen Willey at Stifel, which represents a 360.7% increase from the current price of $3.69.
What is the lowest forecasted price for ABCL AbCellera Biologics Inc.?
The lowest price target for ABCL is $4.00 from Faisal Khurshid at Leerink Partners, which represents a 8.4% increase from the current price of $3.69.
What is the overall ABCL consensus from analysts for AbCellera Biologics Inc.?
The overall analyst consensus for ABCL is bullish. Out of 13 Wall Street analysts, 6 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $8.50.
How accurate are ABCL stock price projections?
Stock price projections, including those for AbCellera Biologics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: November 15, 2025 6:57 AM UTC